AstraZeneca (AZN) DIvidends Date & History

Key Takeaways

• AstraZeneca (AZN) pays a semi-annual dividend of roughly $3.20 per American Depositary Share (ADS), equating to a dividend yield near 1.8%.
• The company maintains a conservative dividend payout ratio of roughly 48% of earnings, leaving ample room for reinvestment and future increases.
• Dividends have grown steadily in the low-to-mid single digits in recent years, supporting a reliable — though modest — income stream.
• As a large-cap pharmaceutical leader, AZN appeals to long-term, total-return-oriented investors rather than high-yield income seekers.
• Compared with large-cap peers, AstraZeneca's yield sits toward the lower end of the pharmaceutical sector.

Dividend Overview

AstraZeneca is a British-Swedish pharmaceutical company with leading franchises in oncology, cardiovascular, renal, metabolic, and rare-disease therapies. The company pays dividends twice a year — once as an interim payment in the autumn and once as a final payment in the spring — rather than on a quarterly schedule common among many U.S. peers. On an American Depositary Share (ADS) basis, AstraZeneca's annualized dividend stands near $3.20, translating to a dividend yield of approximately 1.8%. This is a modest yield by income standards, and AZN is best characterized as a dividend growth stock with a conservative payout rather than a high-yield or income-focused holding. Management's long-standing policy has favored maintaining and modestly raising the dividend while prioritizing research and development investment and balance-sheet strength.

Dividend History and Growth

AstraZeneca has a long and dependable record of returning cash to shareholders. Annual dividends per ADS have climbed from roughly $2.90 in 2022 and 2023 to about $3.10 in 2024 and $3.20 in 2025, with recent yearly increases in the low single digits. The most recent final dividend of approximately $2.17 per ADS went ex-dividend on February 20, 2026, and was paid on March 23, 2026, following an interim payment of about $1.03 that went ex-dividend in August 2025. Growth in the dividend has been measured and consistent rather than aggressive, reflecting the company's balanced capital-allocation philosophy. While AstraZeneca does not carry the decades-long dividend-growth streak of some American dividend aristocrats, its payout has remained reliable and has generally trended upward in recent years.

Dividend Sustainability and Payout Ratio

AstraZeneca's dividend appears well covered. The company's payout ratio — the share of earnings distributed as dividends — is approximately 48%, a level that leaves significant earnings retained for reinvestment in its pipeline and operations. On a free-cash-flow basis, coverage is tighter but still adequate, with the dividend supported by AstraZeneca's strong and growing pharmaceutical franchises. The company's earnings cover has improved in recent years, with dividend cover rising to roughly 1.9 times by 2025, according to analyst estimates. AstraZeneca also maintains a solid financial position relative to its scale, and its diversified revenue base across oncology, cardiovascular, and rare-disease products provides stability. Overall, the conservative payout ratio and improving earnings coverage suggest the dividend is sustainable, with headroom for continued modest increases.

Dividend Compared to Industry Peers

Within the large-cap pharmaceutical sector, AstraZeneca's roughly 1.8% yield sits at the lower end of the range. For comparison, JNJ (Johnson & Johnson) typically yields around 3%, MRK (Merck) near 3%, and PFE (Pfizer) has offered yields above 6%. ABBV (AbbVie) has historically yielded roughly 3% to 4%, while growth-oriented LLY (Eli Lilly) yields well under 1%. This places AstraZeneca between the high-yield value names and the low-yield growth names, consistent with its profile as a pharmaceutical company balancing steady income with strong innovation-driven growth. Investors seeking maximum current income may find higher yields elsewhere in the sector, but AstraZeneca's dividend is supported by a growing business and a conservative payout.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool that helps traders and investors filter the market using technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs with customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener can also help identify dividend stocks, income-focused investments, trending stocks, and breakout candidates far more efficiently than manual screening. For investors researching pharmaceutical names like AZN, the AI Screener offers a streamlined way to compare yields, payout profiles, and technical setups across the sector. Explore the AI Screener to refine your dividend and growth watchlist.

Is This Stock Attractive for Dividend Investors?

AstraZeneca is best suited to long-term, total-return-oriented investors who value a reliable and gradually growing dividend alongside strong business fundamentals, rather than those seeking immediate high income. Its sub-2% yield will not satisfy income-focused investors looking for meaningful cash flow today, particularly when higher-yielding pharmaceutical peers are available. However, the conservative payout ratio, improving earnings coverage, and diversified, innovation-led growth profile make the dividend appear sustainable and capable of modest future increases. Dividend growth investors may appreciate the steady, predictable nature of the payout, though growth has been incremental rather than rapid. Conservative and long-term investors may find AstraZeneca an attractive component of a diversified portfolio, with the dividend serving as a modest supplement to potential capital appreciation. As with any equity, the dividend depends on continued earnings and cash-flow generation.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations